Literature DB >> 12360257

Toll-like receptors as potential therapeutic targets for multiple diseases.

Claudia Zuany-Amorim1, John Hastewell, Christoph Walker.   

Abstract

The family of Toll-like receptors (TLRs) is receiving considerable attention as potential regulators and controllers of the immune response through their ability to recognize pathogen-associated molecular patterns. The discovery that endogenous ligands, as well as microbial components, are recognized by TLRs, and that small-molecular-mass synthetic compounds activate TLRs, raised interest in these receptors as potential targets for the development of new therapies for multiple diseases. In this review, we discuss the current and future use of TLR agonists or antagonists in chronic inflammatory diseases and highlight potential problems that are associated with such approaches.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360257     DOI: 10.1038/nrd914

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  63 in total

1.  Immunopharmacology of CpG oligodeoxynucleotides and ribavirin.

Authors:  Jörg Vollmer; Robert Rankin; Hanna Hartmann; Marion Jurk; Ulrike Samulowitz; Tanja Wader; Andrea Janosch; Christian Schetter; Arthur M Krieg
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 2.  B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors:  Robert H Carter
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 3.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  Development of a Grp94 inhibitor.

Authors:  Adam S Duerfeldt; Laura B Peterson; Jason C Maynard; Chun Leung Ng; Davide Eletto; Olga Ostrovsky; Heather E Shinogle; David S Moore; Yair Argon; Christopher V Nicchitta; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2012-05-29       Impact factor: 15.419

5.  Toll-like receptor 4-dependent early elicited tumor necrosis factor alpha expression is critical for innate host defense against Bordetella bronchiseptica.

Authors:  Paul B Mann; Kelly D Elder; Mary J Kennett; Eric T Harvill
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Toll-like receptor 3 regulates Mx expression in rare minnow Gobiocypris rarus after viral infection.

Authors:  Jianguo Su; Zuoyan Zhu; Yaping Wang; Jun Zou; Wei Hu
Journal:  Immunogenetics       Date:  2008-03-28       Impact factor: 2.846

7.  Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model.

Authors:  K Takashima; N Matsunaga; M Yoshimatsu; K Hazeki; T Kaisho; M Uekata; O Hazeki; S Akira; Y Iizawa; M Ii
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 8.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

9.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

10.  Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia.

Authors:  Sandra Ribes; Sandra Ebert; Tommy Regen; Amit Agarwal; Simone C Tauber; Dirk Czesnik; Annette Spreer; Stephanie Bunkowski; Helmut Eiffert; Uwe-Karsten Hanisch; Sven Hammerschmidt; Roland Nau
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.